P-500

News alerts, weekly reports and conference planners

Company:

Pathos, Prelude Therap

Drug class:

PRMT5 inhibitor

Related drugs:

IDH2 mutation	Glioma	IDH2 mutation	Glioma	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3
IDH1 mutation	Glioma	IDH1 mutation	Glioma	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + P-500 Sensitive: D – Preclinical gilteritinib + P-500 Sensitive : D	gilteritinib + P-500 Sensitive: D – Preclinical gilteritinib + P-500 Sensitive : D

Associations
(3)